VENCLÍČEK, Ondřej, Jana SKŘIČKOVÁ, Kristián BRAT, Ondrej FISCHER, Libor HAVEL, Michal HRNCIARIK, Miloslav MAREL, Petr OPALKA, Gabriela KRAKOROVA, Denisa ROZSIVALOVA, Juraj KULTAN, Andrea MULLEROVA, Lydia ZARNAYOVA, Petra SMICKOVA, Martina VASAKOVA, Zsuzsanna GYORFY, Michal JIROUSEK, Daniel KREJCI, Jana KREJCI, Petr ZUNA, Martin SVATON, Kristyna HRDA, Jaroslav DUBA, Jana ALAHAKOON, Michal SVOBODA and Jiri SILAR. Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry. Anticancer Research. Athens: International Institute of Anticancer Research, 2021, vol. 41, No 11, p. 5549-5556. ISSN 0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.15368.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry
Authors VENCLÍČEK, Ondřej (203 Czech Republic, guarantor, belonging to the institution), Jana SKŘIČKOVÁ (203 Czech Republic, belonging to the institution), Kristián BRAT (703 Slovakia, belonging to the institution), Ondrej FISCHER (203 Czech Republic), Libor HAVEL (203 Czech Republic), Michal HRNCIARIK (203 Czech Republic), Miloslav MAREL (203 Czech Republic), Petr OPALKA (203 Czech Republic), Gabriela KRAKOROVA (203 Czech Republic), Denisa ROZSIVALOVA (203 Czech Republic), Juraj KULTAN (203 Czech Republic), Andrea MULLEROVA (203 Czech Republic), Lydia ZARNAYOVA (203 Czech Republic), Petra SMICKOVA (203 Czech Republic), Martina VASAKOVA (203 Czech Republic), Zsuzsanna GYORFY (203 Czech Republic), Michal JIROUSEK (203 Czech Republic), Daniel KREJCI (203 Czech Republic), Jana KREJCI (203 Czech Republic), Petr ZUNA (203 Czech Republic), Martin SVATON (203 Czech Republic), Kristyna HRDA (203 Czech Republic), Jaroslav DUBA (203 Czech Republic), Jana ALAHAKOON (203 Czech Republic), Michal SVOBODA (203 Czech Republic, belonging to the institution) and Jiri SILAR (203 Czech Republic).
Edition Anticancer Research, Athens, International Institute of Anticancer Research, 2021, 0250-7005.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Greece
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.435
RIV identification code RIV/00216224:14110/21:00123236
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.21873/anticanres.15368
UT WoS 000720235500001
Keywords in English Lung cancer; non-smokers; clinical registry; NSCLC; survival; driving mutations
Tags 14110215, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 13/12/2021 12:33.
Abstract
Background/Aim: LUCAS is a clinical lung cancer registry (ClinicalTrials.gov identifier is NCT04228237), prospectively collecting data from newly diagnosed lung cancer patients in seven pneumooncology centers in the Czech Republic, since June 1, 2018. The aim of the study was to assess the stage of the disease at the time of diagnosis, percentage of morphological types, survival, percentage of driving mutations, eligibility for radical surgery, and percentage of patients who undergo radical surgery, in the non-smoking population in comparison with smokers and former smokers. Patients and Methods: The total number of patients in the registry at the time of the analysis was 2,743. Only 2,439 patients with complete records (smoking status, stage, and type of tumor) were included in this study. Results: The analysis indicated that non-smokers are diagnosed at a later stage of the disease but they have a better survival rate than smokers. Fewer smokers with stage III disease who are eligible for radical surgery will undergo surgery compared to non-smokers with the same clinical stage. Driving mutations are more common in non-smokers, even after adjustment for the more frequent occurrence of adenocarcinoma in the group of non-smokers. Conclusion: The data from LUCAS registry are consistent with already known facts, suggesting that the LUCAS registry is a useful clinical tool.
PrintDisplayed: 21/7/2024 06:26